Sebetralstat is a small molecule commercialized by Kalvista Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 10 clinical trials, of which 6 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sebetralstat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Sebetralstat is expected to reach an annual total of $517 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sebetralstat Overview
Sebetralstat (KVD-900) is under development for the treatment of hereditary angioedema. The drug candidate is administered through oral route in the form of the tablet. It acts by targeting plasma kallikrein.
Kalvista Pharmaceuticals Overview
Kalvista Pharmaceuticals, Inc. is a pharmaceutical company that is into the discovery, development, and commercialization of oral, small-molecule protease inhibitors for diseases with significant unmet needs. The company’s product pipeline includes sebetralstat, oral factor Xlla and KVD001. Its pipeline candidates treat hereditary angioedema, prophylaxis in hereditary angioedema, thrombosis inflammation and diabetic macular edema. Kalvista is also progressing additional oral candidates toward regulatory preclinical studies. The company has its operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Sebetralstat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
